HMS News article on a new experimental treatment that shows promise in slowing the progression of amyotrophic lateral sclerosis (ALS), in a clinical trial run by investigators at MGH and Amylyx Pharmaceuticals, led by principal investigator Sabrina Paganoni and senior author Merit Cudkowicz.